L&P Client Murray & Poole Victorius at PTAB in IPR Challenging All Claims of Drug Patent

Today the Patent Trial and Appeal Board (PTAB) of the USPTO (United States Patent and Trademark Office) issued a final written decision invalidating U.S. Patent No. 11,400,063, owned by Institut de Cardiologie de Montreal and entitled “Early Administration of Low-Dose Colchicine After Myocardial Infarction.”  The decision came in an inter partes review (IPR) filed on behalf of Murray & Poole Enterprises Ltd.  The PTAB’s decision found all claims of the ’063 Patent unpatentable.  L&P lawyers Kevin Laurence and Matt Phillips worked on the case with BioPharma Law Group PLLC.